Multicenter Phase II Study of Reduced-Dose CHOP Chemotherapy Combined with Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma
ConclusionsOutcomes of RD-RCHOP chemotherapy were comparable to those of standard dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy. In the future, strategies such as tailored therapy based on the geriatric assessment are needed to determine the chemotherapeutic dosage.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Geriatrics | Leukemia | Lymphoma | Myeloma | Prednisolone | Prednisone | Rituxan | Study | Toxicology